Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn
Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Novartis raises mid-term sales outlook on pipeline promise
Novartis has raised its guidance for sales growth out to 2029 on the strength of its pipeline and the potential of late-stage R&D assets
Eisai debuts biliary tract cancer drug in Japan
Eisai has launched its new therapy for biliary tract cancer (BTC) Tasfygo in Japan, the first world market for the FGFR-targeting drug
23andMe stock sell-off adds to its woes
Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
Pfizer elevates Chris Boshoff to top R&D role
Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
9th Commercialising Continuous Processing Summit 2025
The pivotal shift in biopharma priorities is steering towards enhancing sustainability measures for drug development.
9th Liquid Biopsy for Precision Oncology Summit
9th Liquid Biopsy for Precision Oncology Summit | February 18-20, 2025 | San Diego, CA | FREE* to Attend for Biopharma
Returning... The 5th Operationalize Expanded Access Programs...
Welcome to, or welcome back to, the 5th Operationalize: Expanded Access Programs Summit 2025!
LEAP HR: Life Sciences Europe
Save the Date for LEAP HR: Life Sciences Europe! 18th-20th February, 2025, London, UK.
Patient Recruitment for Rare Disease Trials Summit
Recruiting patients for rare disease trials is akin to finding a needle in a haystack, with challenges such as geographical dispersion, low awareness, and limited eligible patient pools.